GIST
Conference Coverage
Conference Coverage: ASCO 2019
Clinical Review
Gastrointestinal Stromal Tumors: Management of Localized Disease
Clinical Review
Gastrointestinal Stromal Tumors: Management of Advanced Disease
Case Reports
Recurrence of a small gastric gastrointestinal stromal tumor with high mitotic index
Conference Coverage
Rapid drug alteration a bust in metastatic GIST
Short alternating cycles of sunitinib with regorafenib failed to reach active drug levels in patients with heavily pretreated disease.
Conference Coverage
ctDNA profiles pre- and posttreatment KIT mutations in GIST
CHICAGO – A broad spectrum KIT inhibitor should be a part of post-imatinib therapy for GIST, data from a phase 1 study suggest.
Conference Coverage
Novel TKI PLX9486 showed efficacy against KIT mutations in GIST
CHICAGO – Combined with another investigational tyrosine kinase inhibitor, the compound showed activity against a broad range of resistance...
Physician Resources
Adult soft tissue sarcoma: Professional resources from the National Cancer Institute
From the Journals
Dasatinib activity prominent in subset of GIST patients
The estimated rate of 6-month progression-free survival was 29% overall, though it was 50% in one biomarker-defined patient subset.
Original Research
Onodera’s Prognostic Nutritional Index in soft tissue sarcoma patients as a predictor of wound complications
Background The ability to predict a wound complication after radiation therapy and surgery for soft tissue sarcomas remains difficult....
Reviews
Soft Tissue Sarcoma: Diagnosis and Treatment
IntroductionSoft tissue sarcomas (STSs) are rare adult tumors, with 3.4 new cases per 100,000 persons or 12,310 expected new cases in 2016.1...